Please login to the form below
Medicxi
This page shows the latest Medicxi news and features for those working in and with pharma, biotech and healthcare.
Novartis and J&J back latest €400m Medicxi biopharma fund
to Medicxi, with European companies growing in stature and offering improved returns on investment for backers. ... to the US, Medicxi’s co-founder Francesco De Rubertis told the Financial Times.
Latest news
-
Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance
The breadth of candidates in Sosei Heptares’ pipeline prompted the company to hive off some neurological programmes into two virtual companies – called Orexia and Inexia - with funding from Medicxi Ventures.
-
Evotec spins off cancer tech into new Breakpoint company
life sciences investor group Medicxi, the venture capital arm of Japanese drugmaker Taiho.
-
Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
Gadeta was founded in 2015 by Professor Jürgen Kuball, Mark de Boer, Utrecht Holdings and venture fund Medicxi, its founding investor.
-
Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding
Two new investors, Medicxi and RA Capital Management, participated in the financing, which will fund the development of T-Guard into phase III registration trials, arranging commercial-scale production and marketing
-
Medicxi aims to plug funding gap for European biotech
Backed by Novartis and Alphabet's Verily unit, Medicxi Ventures has set up a $300m biotech fund that will back European growth-stage biotechs - that it says do not have access ... The European life sciences sector is recognised for its innovation, but
Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance
Evotec spins off cancer tech into new Breakpoint company
Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding
Medicxi aims to plug funding gap for European biotech
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Building European biotech firms to rival those of the US
Richard Mason (pictured above) is a veteran of the UK biotech industry, including a spell as CEO of company XO1 set up by venture capital investors Index Ventures (now Medicxi) in
-
European biotech: a new generation of leaders emerges
One key venture capital fund is London-based Medicxi, which raised 400m ($450m) from investors earlier this year for its third biopharma development fund. ... Medicxi III will be also supported by the investment firm’s scientific advisory board, which
Building European biotech firms to rival those of the US
European biotech: a new generation of leaders emerges
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Medicxi appoints former GSK chair Moncef Slaoui
He joins the life science investment firm as a partner. London, UK-based life science investment group Medicxi has appointed former GSK chairman of pharmaceutical R&D, vaccines Dr Moncef Slaoui ... He said: “Having developed a strong relationship with
Medicxi appoints former GSK chair Moncef Slaoui
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Associate Account Director
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Senior Medical Writer
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Account Management
-
Competitive Salary Offered
-
Senior Account Executive
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Publications Director
-
Competitive Salary
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
